PAM Stock Recent News

Pampa Energía is leveraging Argentina's macro stabilization to consolidate its leadership in power and gas, while expanding regionally and investing in strategic LNG, shale oil, and renewables projects. Operational strength continues: thermal availability at 96%, PEPE 6 fully running, and Rincón de Aranda progressing fast toward 20,000 bpd. The FLNG project also confirmed with global partners. Financials remain solid with just 0.6x net debt/EBITDA, over $1.1B in cash, and strong margins. PAM funds growth without borrowing or shareholder dilution.

Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2025 financial results and provided a corporate update.

PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) introduces the industry's first ReDriver™ to reach PCI Express® (PCIe®) 6.0 protocol speeds (up to 64 GT/s) while being backwards-compatible with PCIe 5.0/4.0/3.0 protocols. The PI3EQX64904 is a low-power, high-performance, 64GT/s, four-differential-channel, PAM4, linear ReDriver. Target applications include AI data centers (storage and servers), workstations, 5G networking, CPU-to-network (PCIe NIC card) and CPU-to-storage (NVME.

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PAM makes a strong case for investment, given its growth prospects, strong ROE, liquidity, better debt management and focus on clean power generation.

Pampa Energia S.A. (NYSE:PAM ) Q1 2025 Results Conference Call May 13, 2025 10:00 AM ET Company Participants Raquel Cardasz - Investor Relations Lida Wang - Investor Relations & Sustainability Officer Gustavo Mariani - Executive Vice President & Chief Executive Officer Horacio Turri - EVP & Executive Director of Exploration & Production Raquel Cardasz Good morning, everyone, and thank you for waiting.

Pampa Energía, a leading electricity producer in Argentina, holds a 15% market share and is highly diversified within the energy sector. The company operates in electric power generation, high-voltage power transmission, liquefied gas transportation, and has recently expanded into oil and gas extraction. Government measures under Alberto Fernández negatively impacted the energy sector, but conditions improved significantly during Milei's presidency.

BUENOS AIRES, ARGENTINA / ACCESS Newswire / May 12, 2025 / Pampa Energía S.A. (NYSE: PAM)(Buenos Aires Stock Exchange:PAMP), an independent company with active participation in Argentine oil, gas and electricity, announces the results for the quarter ended on March 31, 2025.

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.